PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 3, 20240 citationsOpen Access

Supplementary Figure 11 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

View Full Paper
ESEric Y. Stutheit-ZhaoUniversity of TorontoESEnrique Sanz‐GarcíaPrincess Margaret Cancer CentreZLZhihui Amy LiuUniversity Health Network

Key Points

Key points are not available for this paper at this time.

Abstract

Multivariable analysis of OS and PFS using cancer mutation concentration (CMC) at baseline and cycle 3 of pembrolizumab. CMC was determined using a bespoke targeted approach across the trial cohort. At both baseline and cycle 3, patients were split into above- or below-median groups. Survival outcomes are shown in a multivariable analysis including cohort, PD-L1 expression, and tumor mutation burden (TMB).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Stutheit-Zhao et al. (2024) studied this question.

synapsesocial.com/papers/68e6672fb6db6435875f3a49https://doi.org/10.1158/2159-8290.25956891.v1
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure 11 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors2024
  2. 2Supplementary Figure 10 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors2024
  3. 3Supplementary Figure 10 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors2024
  4. 4Supplementary Figure 12 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors2024
  5. 5Supplementary Figure 12 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors2024